Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Neoplasm Metastasis 3 Neoplasm, Residual 1 Lymphoproliferative Disorders 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Immunoglobulin Light-chain Amyloidosis 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Amyloidosis 1

Interventions

Carboplatin 345 Cisplatin 240 Paclitaxel 208 Radiotherapy 206 Pemetrexed 190 Docetaxel 170 Gemcitabine 158 pembrolizumab 146 Erlotinib Hydrochloride 111 Magnetic Resonance Spectroscopy 101 Etoposide 98 Bevacizumab 96 Specimen Handling 84 Nivolumab 77 durvalumab 73 Radiosurgery 73 Blood Specimen Collection 65 Drug Therapy 61 osimertinib 56 Vinorelbine 54 Gefitinib 50 Surveys and Questionnaires 48 atezolizumab 44 Biopsy 43 Irinotecan 42 Radiation 41 Topotecan 39 Standard of Care 38 Cyclophosphamide 38 Surgical Procedures, Operative 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × Biological Assay × Clear all

NCT06716580 2025-12-10

EQUAL

Dana-Farber Cancer Institute

Phase NA Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡